Related references
Note: Only part of the references are listed.Adherence to immunomodulatory drugs in patients with multiple myeloma
Amelie Cransac et al.
PLOS ONE (2019)
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
Ronan Le Calloch et al.
HAEMATOLOGICA (2018)
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
Ronan Le Calloch et al.
HAEMATOLOGICA (2018)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Francesca Palandri et al.
ONCOTARGET (2017)
Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations
Anna Rachelle Mislang et al.
CANCER TREATMENT REVIEWS (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Predictors of adherence to medication in older Korean patients with hypertension
Yeon-Hwan Park et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING (2013)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Srdan Verstovsek et al.
BLOOD (2012)
Unintentional non-adherence to chronic prescription medications: How unintentional is it really?
Abhijit S. Gadkari et al.
BMC HEALTH SERVICES RESEARCH (2012)
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
F. Efficace et al.
BRITISH JOURNAL OF CANCER (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Patient Adherence and Persistence With Oral Anticancer Treatment
Kathryn Ruddy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
被撤回的出版物: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting (Retracted article. See AUG, 2023)
Donald E. Morisky et al.
JOURNAL OF CLINICAL HYPERTENSION (2008)
Self-reported adherence versus pill count in Parkinson's disease: The NET-PD experience
Jordan J. Elm et al.
MOVEMENT DISORDERS (2007)
An RCT of the effect of motivational interviewing on medication adherence in hypertensive African Americans: Rationale and design
Gbenga Ogedegbe et al.
CONTEMPORARY CLINICAL TRIALS (2007)
Relationships between beliefs about medications and nonadherence to prescribed chronic medications
Hemant M. Phatak et al.
ANNALS OF PHARMACOTHERAPY (2006)
Intentional and unintentional nonadherence: A study of decision making
AL Wroe
JOURNAL OF BEHAVIORAL MEDICINE (2002)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
